Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jul;95(7):1046-8.
doi: 10.3324/haematol.2010.024885.

Positron emission tomography scanning: a new paradigm for the management of Hodgkin's lymphoma

Andrea Gallamini
Review

Positron emission tomography scanning: a new paradigm for the management of Hodgkin's lymphoma

Andrea Gallamini. Haematologica. 2010 Jul.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Guidelines for the clinical use of PET in Hodgkin’s lymphoma and diffuse large B-cell lymphoma (Adapted from Cheson et al.)
See this image and copyright information in PMC

References

    1. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107(1):52–9. - PubMed
    1. Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease. Haematologica. 2006;91(4):475–81. - PubMed
    1. Dann EJ, Bar-Shalom R, Tamir A, Epelbaum R, Avivi I, Ben-Shachar M, et al. A functional dynamic scoring model to elucidate the significance of post-induction interim fluorine-18-fluorodeoxyglucose positron emission tomography findings in patients with Hodgkin’s lymphoma. Haematologica. 2010;95(7):1198–206. - PMC - PubMed
    1. Diehl V, Stein H, Hummel M, Zollinger R, Connors JM. Hodgkin’s lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology Am Soc Hematol Educ Program. 2003:225–47. - PubMed
    1. Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol. 1988;6(6):931–3. - PubMed